Research graph
References from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Breast cancer statistics 2024
10.3322/caac.21863 · 2024 · External reference
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
10.1016/s1470-2045(19)30804-6 · 2020 · External reference
CDK4/6 inhibitors in HR+/HER2− advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies
10.2217/fon-2020-1264 · 2021 · External reference
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
10.1038/s41467-019-09068-2 · 2019 · External reference
The genomic landscape of endocrine-resistant advanced breast cancers
10.1016/j.ccell.2018.08.008 · 2018 · External reference
Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer
10.1158/1078-0432.ccr-19-3958 · 2020 · External reference
Abstract 6744: cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: a multi-institutional analysis of incidence and clinical outcomes
10.1158/1538-7445.am2023-6744 · 2023 · External reference
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
10.1038/s41467-024-45835-6 · 2024 · External reference
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer
10.1158/2159-8290.cd-19-1390 · 2020 · External reference
MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer
10.1158/1078-0432.ccr-18-0410 · 2018 · External reference
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity
10.1158/0008-5472.can-12-3937 · 2013 · External reference
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
10.1016/s1470-2045(20)30464-2 · 2020 · External reference
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial
10.1038/s41591-025-03763-y · 2025 · External reference
FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
External reference
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
10.1200/jco.2023.41.16_suppl.5515 · 2023 · External reference
Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
10.1200/jco-25-00112 · 2025 · External reference
Thymidine kinase 1 through the ages: a comprehensive review
10.1186/s13578-020-00493-1 · 2020 · External reference
Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update
10.1200/jco.2018.77.8738 · 2018 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Bayesian optimal interval design for dose finding in drug-combination trials
10.1177/0962280215594494 · 2017 · External reference
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
10.1080/1354750x.2023.2168063 · 2023 · External reference
510(k) Substantial equivalence determination decision summary assay only
External reference
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors
10.1007/s10549-025-07879-0 · 2026 · External reference
Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors
10.1158/2159-8290.cd-16-0095 · 2016 · External reference
Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4/6 inhibition: results from the phase III postMONARCH trial
10.1200/jco-24-02086 · 2025 · External reference
VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor–positive/HER2−/PIK3CA wild-type advanced breast cancer
10.1200/jco-25-02643 · 2026 · External reference
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial
10.1200/jco.22.00338 · 2022 · External reference
Capivasertib in hormone receptor–positive advanced breast cancer
10.1056/nejmoa2214131 · 2023 · External reference
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
10.1016/j.ygyno.2024.01.028 · 2024 · External reference
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
10.1016/j.ejca.2021.12.030 · 2022 · External reference
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial
10.1016/j.ejca.2023.03.001 · 2023 · External reference
Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial
10.1158/1078-0432.ccr-19-3271 · 2020 · External reference
Real-world plasma thymidine kinase activity in high-risk and metastatic hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer treated with cyclin-dependent kinase 4/6 inhibitors
10.1200/po-25-00346 · 2026 · External reference
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
10.1038/s41523-022-00399-w · 2022 · External reference
Evaluating serum thymidine kinase 1 in patients with hormone receptor–positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial
10.1158/1078-0432.ccr-21-1562 · 2021 · External reference
Plasma thymidine kinase activity as a novel biomarker in metastatic melanoma patients treated with immune checkpoint inhibitors
10.3390/cancers14030702 · 2022 · External reference
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
10.1136/jitc-2024-010430 · 2025 · External reference
CDK4/6 inhibition triggers anti-tumour immunity
10.1038/nature23465 · 2017 · External reference
The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy
10.1042/etls20170142 · 2017 · External reference
Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: MAINTAIN trial
10.1200/jco.22.02392 · 2023 · External reference
Imlunestrant with or without abemaciclib in advanced breast cancer
10.1056/nejmoa2410858 · 2025 · External reference
Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients
10.1200/jco.22.00371 · 2022 · External reference
